Meet Your ETF AI Analyst
EQL Pharma AB ( (SE:EQL) ) has provided an update.
EQL Pharma AB has received marketing approval in Germany for its key product, methenamine hippurate, branded as Cystohipp, which will be launched in mid-2026. This product provides German patients with recurrent urinary tract infections a non-antibiotic alternative, addressing a significant need for treatments that do not contribute to antibiotic resistance. The market potential is optimistic, with expectations of rapid growth due to the clear demand for such…
